vs
Side-by-side financial comparison of APTARGROUP, INC. (ATR) and Hims & Hers Health, Inc. (HIMS). Click either name above to swap in a different company.
APTARGROUP, INC. is the larger business by last-quarter revenue ($962.7M vs $617.8M, roughly 1.6× Hims & Hers Health, Inc.). APTARGROUP, INC. runs the higher net margin — 7.7% vs 3.3%, a 4.4% gap on every dollar of revenue. On growth, Hims & Hers Health, Inc. posted the faster year-over-year revenue change (28.4% vs 13.5%). APTARGROUP, INC. produced more free cash flow last quarter ($96.9M vs $-2.5M). Over the past eight quarters, Hims & Hers Health, Inc.'s revenue compounded faster (49.0% CAGR vs 2.6%).
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
Hims & Hers Health, Inc. is an American telehealth company established in 2017. The company provides prescription medications, over-the-counter medications, and personal care products.
ATR vs HIMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $962.7M | $617.8M |
| Net Profit | $74.3M | $20.6M |
| Gross Margin | — | 71.9% |
| Operating Margin | 11.0% | 1.5% |
| Net Margin | 7.7% | 3.3% |
| Revenue YoY | 13.5% | 28.4% |
| Net Profit YoY | -26.4% | -20.8% |
| EPS (diluted) | $1.13 | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $962.7M | $617.8M | ||
| Q3 25 | $961.1M | $599.0M | ||
| Q2 25 | $966.0M | $544.8M | ||
| Q1 25 | $887.3M | $586.0M | ||
| Q4 24 | $848.1M | $481.1M | ||
| Q3 24 | $909.3M | $401.6M | ||
| Q2 24 | $910.1M | $315.6M | ||
| Q1 24 | $915.4M | $278.2M |
| Q4 25 | $74.3M | $20.6M | ||
| Q3 25 | $127.9M | $15.8M | ||
| Q2 25 | $111.7M | $42.5M | ||
| Q1 25 | $78.8M | $49.5M | ||
| Q4 24 | $100.9M | $26.0M | ||
| Q3 24 | $100.0M | $75.6M | ||
| Q2 24 | $90.5M | $13.3M | ||
| Q1 24 | $83.1M | $11.1M |
| Q4 25 | — | 71.9% | ||
| Q3 25 | — | 73.8% | ||
| Q2 25 | — | 76.4% | ||
| Q1 25 | — | 73.5% | ||
| Q4 24 | — | 76.8% | ||
| Q3 24 | — | 79.2% | ||
| Q2 24 | — | 81.3% | ||
| Q1 24 | — | 82.4% |
| Q4 25 | 11.0% | 1.5% | ||
| Q3 25 | 14.2% | 2.0% | ||
| Q2 25 | 14.9% | 4.9% | ||
| Q1 25 | 12.8% | 9.9% | ||
| Q4 24 | 14.2% | 3.9% | ||
| Q3 24 | 15.2% | 5.6% | ||
| Q2 24 | 13.8% | 3.5% | ||
| Q1 24 | 12.2% | 3.6% |
| Q4 25 | 7.7% | 3.3% | ||
| Q3 25 | 13.3% | 2.6% | ||
| Q2 25 | 11.6% | 7.8% | ||
| Q1 25 | 8.9% | 8.4% | ||
| Q4 24 | 11.9% | 5.4% | ||
| Q3 24 | 11.0% | 18.8% | ||
| Q2 24 | 9.9% | 4.2% | ||
| Q1 24 | 9.1% | 4.0% |
| Q4 25 | $1.13 | $0.08 | ||
| Q3 25 | $1.92 | $0.06 | ||
| Q2 25 | $1.67 | $0.17 | ||
| Q1 25 | $1.17 | $0.20 | ||
| Q4 24 | $1.48 | $0.10 | ||
| Q3 24 | $1.48 | $0.32 | ||
| Q2 24 | $1.34 | $0.06 | ||
| Q1 24 | $1.23 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $409.5M | $228.6M |
| Total DebtLower is stronger | $1.1B | — |
| Stockholders' EquityBook value | $2.7B | $540.9M |
| Total Assets | $5.3B | $2.2B |
| Debt / EquityLower = less leverage | 0.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $409.5M | $228.6M | ||
| Q3 25 | $264.8M | $345.8M | ||
| Q2 25 | $169.8M | $1.1B | ||
| Q1 25 | $136.8M | $273.7M | ||
| Q4 24 | $226.2M | $220.6M | ||
| Q3 24 | $327.9M | $165.5M | ||
| Q2 24 | $223.9M | $129.3M | ||
| Q1 24 | $201.1M | $105.2M |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | — | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — | ||
| Q1 24 | $680.4M | — |
| Q4 25 | $2.7B | $540.9M | ||
| Q3 25 | $2.8B | $581.0M | ||
| Q2 25 | $2.7B | $562.7M | ||
| Q1 25 | $2.5B | $549.3M | ||
| Q4 24 | $2.5B | $476.7M | ||
| Q3 24 | $2.5B | $440.1M | ||
| Q2 24 | $2.4B | $362.0M | ||
| Q1 24 | $2.3B | $344.5M |
| Q4 25 | $5.3B | $2.2B | ||
| Q3 25 | $5.1B | $2.2B | ||
| Q2 25 | $4.9B | $1.9B | ||
| Q1 25 | $4.5B | $891.7M | ||
| Q4 24 | $4.4B | $707.5M | ||
| Q3 24 | $4.6B | $602.3M | ||
| Q2 24 | $4.5B | $480.5M | ||
| Q1 24 | $4.4B | $448.1M |
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.7M | $61.3M |
| Free Cash FlowOCF − Capex | $96.9M | $-2.5M |
| FCF MarginFCF / Revenue | 10.1% | -0.4% |
| Capex IntensityCapex / Revenue | 9.0% | 10.3% |
| Cash ConversionOCF / Net Profit | 2.47× | 2.98× |
| TTM Free Cash FlowTrailing 4 quarters | $299.6M | $57.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.7M | $61.3M | ||
| Q3 25 | $177.6M | $148.7M | ||
| Q2 25 | $126.0M | $-19.1M | ||
| Q1 25 | $82.7M | $109.1M | ||
| Q4 24 | $178.2M | $86.4M | ||
| Q3 24 | $229.3M | $85.3M | ||
| Q2 24 | $143.6M | $53.6M | ||
| Q1 24 | $92.3M | $25.8M |
| Q4 25 | $96.9M | $-2.5M | ||
| Q3 25 | $114.3M | $79.3M | ||
| Q2 25 | $62.5M | $-69.5M | ||
| Q1 25 | $25.9M | $50.1M | ||
| Q4 24 | $112.2M | $59.5M | ||
| Q3 24 | $162.7M | $79.4M | ||
| Q2 24 | $75.4M | $47.6M | ||
| Q1 24 | $16.7M | $11.8M |
| Q4 25 | 10.1% | -0.4% | ||
| Q3 25 | 11.9% | 13.2% | ||
| Q2 25 | 6.5% | -12.8% | ||
| Q1 25 | 2.9% | 8.5% | ||
| Q4 24 | 13.2% | 12.4% | ||
| Q3 24 | 17.9% | 19.8% | ||
| Q2 24 | 8.3% | 15.1% | ||
| Q1 24 | 1.8% | 4.3% |
| Q4 25 | 9.0% | 10.3% | ||
| Q3 25 | 6.6% | 11.6% | ||
| Q2 25 | 6.6% | 9.3% | ||
| Q1 25 | 6.4% | 10.1% | ||
| Q4 24 | 7.8% | 5.6% | ||
| Q3 24 | 7.3% | 1.5% | ||
| Q2 24 | 7.5% | 1.9% | ||
| Q1 24 | 8.3% | 5.0% |
| Q4 25 | 2.47× | 2.98× | ||
| Q3 25 | 1.39× | 9.43× | ||
| Q2 25 | 1.13× | -0.45× | ||
| Q1 25 | 1.05× | 2.20× | ||
| Q4 24 | 1.77× | 3.32× | ||
| Q3 24 | 2.29× | 1.13× | ||
| Q2 24 | 1.59× | 4.03× | ||
| Q1 24 | 1.11× | 2.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
HIMS
Segment breakdown not available.
